查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2023-2030 年全球抗毒市场
市场调查报告书
商品编码
1311878

2023-2030 年全球抗毒市场

Global Anti-Venom Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 133 Pages | 商品交期: 2-3个工作天内

价格

在预测期内（2023-2030 年），全球抗毒血清市场预计将以 7.0% 的复合年增长率增长。抗毒血清通常被称为毒液抗血清，是一种用于治疗被毒蛇、蜘蛛、蝎子等动物以及水母或锥螺等一些海洋物种咬伤或蛰伤症状的药物。扩大全球市场的主要因素包括蛇毒提取方法的改进、蛇毒的治疗潜力以及人们对天然产品的渴望。据世界卫生组织（WHO）统计，每年约有 540 万起蛇咬伤事件，导致 180 万至 270 万起中毒事件（蛇咬伤中毒）。因此，市场参与者意识到了这一需求，并通过生产和销售抗蛇毒产品来满足这一需求。例如，2022 年 8 月，印度科学研究院（IISc）班加罗尔分院的 "毒液进化实验室 "与巴拉特血清和疫苗有限公司（BSV）合作，开发了地区性抗蛇毒产品。(BSV) 合作，在印度研制针对特定地区的蛇咬伤抗蛇毒血清。

细分市场前景

全球抗蛇毒血清市场根据物种、抗蛇毒血清类型、作用方式和最终用户进行细分。根据种类，市场被细分为蛇、蝎子、蜘蛛和其他。根据抗毒血清类型，市场被细分为多价抗毒血清和单价抗毒血清。此外，根据作用方式，市场还可细分为细胞毒性、神经毒性、血液毒性、心脏毒性、肌毒性等。在终端用户中，市场被细分为医院、诊所和非住院手术中心。

预计多价抗毒血清细分市场将在全球抗毒血清市场中占据相当大的份额

蛇咬伤事件的增加、人们对蛇咬伤认识的提高以及产品供应的改善共同推动了多价抗蛇毒血清市场的快速增长。在预测期内，预计多价抗蛇毒血清将占据相当大的市场份额。多价抗蛇毒血清由抗体组成，可中和来自不同物种和属的多种同源毒液。多价蛇类抗蛇毒血清的有效成分包括大班蛇抗蛇毒血清、死亡加藤蛇抗蛇毒血清、褐蛇抗蛇毒血清和虎蛇毒血清。即使在毒蛇种类不明、无法选择单价抗蛇毒血清的情况下，多价抗蛇毒血清也能挽救受害者的生命。多价抗蛇毒血清因其明显的优势而成为最常用的抗蛇毒血清药物。

区域展望

全球抗蛇毒血清市场根据地域进一步细分，包括北美（美国和加拿大）、欧洲（英国、意大利、西班牙、德国、法国和欧洲其他地区）、亚太地区（印度、中国、日本、韩国和亚洲其他地区）和世界其他地区（中东和非洲以及拉丁美洲）。其中，由于 CroFab、Smithsonian、Rare Disease Therapeutics Inc.

北美有望在全球抗蛇毒市场中保持显著的复合年增长率

由于该地区毒蛇咬伤和其他危险咬伤的发生率较高，公众对毒蛇咬伤的认识不断提高，技术不断改进，这些都是预计该市场将占据相当大份额的一些主要因素。在北美，美国预计将对市场扩张产生相当大的影响。根据美国疾病控制和预防中心（CDC）2021 年 6 月发表的一篇文章，美国每年约有 7000-8000 人被毒蛇咬伤。雇员被毒蛇咬伤后非但不会死亡，反而更有可能受到长期伤害。由于蛇咬伤在美国非常普遍，预计市场将因对其疗法需求的增加而上升。此外，重要的关键市场参与者的产品批准和战略倡议预计也将推动该国市场的扩张。例如，2022 年 3 月，Ophirex 公司宣布美国食品和药物管理局已将 varespladib-methyl（"口服 varespladib"）指定为治疗蛇咬伤的快速通道药物。

市场参与者展望

服务于抗蛇毒血清市场的主要公司包括巴拉特血清和疫苗有限公司（Bharat Serums and Vaccines Ltd.(BSV）、勃林格殷格翰国际有限公司（Boehringer Ingelheim International GmbH）、辉瑞公司（Pfizer Inc.公司、BTG 国际公司、罕见病治疗公司等。为了保持市场竞争力，市场参与者采取了各种策略，包括并购、建立伙伴关系、合作、融资和推出新产品等，从而大大促进了市场的增长。例如，2022 年 8 月，总部位于印度的生物制药机构巴拉特血清和疫苗公司（BSV）与印度班加罗尔科学研究所（IISc）的 "进化基因组学实验室 "建立了战略合作伙伴关系，共同研制针对特定地区的抗蛇毒血清，为该国下一代蛇咬伤治疗方法的开发铺平了道路。

报告内容包括

  • 2022 年的市场价值数据分析以及到 2030 年的预测。
  • 各细分市场的年化市场收入（百万美元）。
  • 主要地区的国别分析。
  • 全球抗毒血清市场的主要运营公司。根据数据的可用性，报告还提供了与新产品发布和相关新闻有关的信息。
  • 通过确定未来强劲增长的关键细分市场，分析商业战略。
  • 市场进入和市场扩张战略分析。
  • 通过确定市场中的 "地位 "来制定竞争战略。

目 录

第 1 章：报告摘要

  • 行业现状分析与增长潜力展望
  • 研究方法和工具
  • 市场细分
    • 按细分市场
    • 按地区

第 2 章：市场概述与洞察

  • 报告范围
  • 分析师洞察与当前市场趋势
    • 主要结论
    • 建议
    • 结论

第 3 章：竞争格局

  • 主要公司分析
  • Bharat Serums and Vaccines Ltd. (BSV)
    • 概述
    • 财务分析
    • SWOT 分析
    • 近期发展
  • Boehringer Ingelheim International GmbH
    • 公司概况
    • 财务分析
    • SWOT 分析
    • 近期发展
  • Boston Scientific Corp.
    • 概述
    • 财务分析
    • SWOT 分析
    • 近期发展
  • 关键战略分析

第四章：市场细分

  • 按物种分類的全球抗蛇毒血清市场
    • 蛇类
    • 蝎子
    • 蜘蛛
    • 其他（海洋动物、昆虫）
  • 按抗毒血清类型分類的全球抗毒血清市场
    • 多价抗毒血清
    • 单价抗毒血清
  • 按作用方式分類的全球抗毒血清市场
    • 细胞毒性
    • 神经毒性
    • 血液毒性
    • 心脏毒性
    • 肌毒性
    • 其他（磷脂酶 A2 (PLA2s)、出血性金属蛋白酶）
  • 按最终用户分類的全球抗血清市场
    • 医院
    • 诊所
    • 门诊手术中心

第 5 章 : 区域分析

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 意大利
    • 西班牙
    • 法国
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 世界其他地区

第 6 章：公司简介

  • Bioclon Institute
  • BTG International Inc.
  • CSL Ltd.
  • Flynn Pharma
  • Haffkine Bio-Pharmaceutical Corp Ltd.
  • Incepta Pharmaceuticals Ltd.
  • Inosan Biopharma
  • Instituto Vital Brazil
  • MicroPharm Ltd.
  • Merck & Co. Inc.
  • Merck KGaA
  • Pfizer Inc.
  • Rare Disease Therapeutics Inc.
  • Sigma-Aldrich Co.
  • VINS Bio Products Ltd.
Product Code: OMR2027477

Title: Global Anti-venom Market Size, Share & Trends Analysis Report by Species (Snake, Scorpion, Spider, and Others), by Anti-Venom Type (Polyvalent Anti-venom and Monovalent Anti-venom), by Mode of Action (Cytotoxic, Neurotoxic, Hemotoxic, Cardiotoxic, Myotoxic, and Others), by End-User (Hospitals, Clinics and Ambulatory Surgical Centers), Forecast Period (2023-2030).

The global anti-venom market is anticipated to grow at a CAGR of 7.0% during the forecast period (2023-2030). Anti-venom, often referred to as venom antiserum, is a type of drug used to treat the symptoms of venomous bites or stings from animals, such as snakes, spiders, scorpions, and some marine species such as jellyfish or cone snails. The major factor expanding the market globally include improvements in venom extraction methods, the therapeutic potential of snake venom, and the desire for natural products. According to the World Health Organization (WHO), every year roughly 5.4 million snake bites, resulting in 1.8 to 2.7 million instances of envenoming's (snake bite poisoning). Hence, the market participants are aware of this demand and are working to satisfy it by creating and distributing anti-venom products. For Instance, in August 2022, The Indian Institute of Science (IISc) Bangalore's 'Evolutionary Venomics Lab' and Bharat Serums and Vaccines Ltd. (BSV) partnered to create region-specific antivenom for snakebites in India.

Segmental Outlook

The global anti-venom market is segmented based on species, anti-venom type, mode of action, and end user. Based on the species, the market is sub-segmented into snake, scorpion, spider, and others. Based on anti-venom type, the market is sub-segmented into polyvalent anti-venom and monovalent anti-venom. Further, on the basis of the mode of action, the market is sub-segmented into cytotoxic, neurotoxic, haemotoxic, cardiotoxic, myotoxic, and others. Among the end user, the market is sub-segmented into hospitals, clinics, and ambulatory surgical centers.

The Polyvalent Anti-venom Sub-Segment is Anticipated to Hold a Considerable Share of the Global Anti-venom Market

The combination of increased snakebite incidents, growing awareness, and improved product offerings has driven the fast growth of the polyvalent antivenom market. Over the course of the forecast period, a sizable market share is anticipated for the polyvalent anti-venoms segment. Polyvalent anti-venoms are made up of antibodies that may neutralize a number of homologous venoms from various species and genera. The active components of polyvalent snake antivenom include taipan antivenom, death adder antivenom, brown snake antivenom, and tiger snake antivenom. Even when the snake responsible for the envenomation is unknown and a monovalent antivenom cannot be selected, polyvalent antivenoms can save the lives of victims. Polyvalent anti-venoms are the most used anti-venom medication due to their evident benefits.

Regional Outlook

The global anti-venom market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia-Pacific is anticipated to hold a prominent share of the market across the globe, owing to the high concentration of the market solution vendors including CroFab, Smithsonian, Rare Disease Therapeutics Inc., and others.

North America is Expected to Hold a Significant CAGR in the Global Anti-Venom Market

Due to the high rate of snakebites and other dangerous bites in the area, the growing public awareness of venomous bites, and growing technological improvements are some of the major factors anticipated to hold a considerable share of the market. In North America, the US is anticipated to have a sizable impact on market expansion. According to a Centers for Disease Control and Prevention (CDC) article published in June 2021, in US around 7,000-8,000 individuals were bitten by venomous snakes every year. Rather than dying from snake bites, employees are much more likely to sustain long-term injuries. Due to snake bites being so common there, the market is anticipated to rise as a result of the rising demand for its therapies. Moreover, Product approvals and strategic moves by important key market players are also anticipated to boost market expansion in the nation. For instance, in March 2022, Ophirex, Inc. declared that the US FDA had given varespladib-methyl ("oral varespladib") Fast Track designation for the treatment of snakebite.

Market Players Outlook

The major companies serving the anti-venom market include: Bharat Serums and Vaccines Ltd. (BSV), Boehringer Ingelheim International GmbH, Pfizer Inc., MicroPharm Ltd., Merck & Co. Inc., and BTG International Inc., Rare Disease Therapeutics Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in August 2022, Bharat Serums and Vaccines (BSV), an India-based biopharmaceutical organization strategically partnered with the "Evolutionary Genomics Lab" at the Indian Institute of Science (IISc) Bangalore to create region-specific antivenoms and pave the way for the country's next-generation snakebite treatment.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global anti-venom market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Bharat Serums and Vaccines Ltd. (BSV)
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Boehringer Ingelheim International GmbH
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Boston Scientific Corp.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Anti-Venom Market by Species
    • 4.1.1. Snake
    • 4.1.2. Scorpion
    • 4.1.3. Spider
    • 4.1.4. Others (Marine animals, Insects)
  • 4.2. Global Anti-Venom Market by Anti-venom Type
    • 4.2.1. Polyvalent Anti-venom
    • 4.2.2. Monovalent Anti-venom
  • 4.3. Global Anti-Venom Market by Mode of Action
    • 4.3.1. Cytotoxic
    • 4.3.2. Neurotoxic
    • 4.3.3. Haemotoxic
    • 4.3.4. Cardiotoxic
    • 4.3.5. Myotoxic
    • 4.3.6. Others (Phospholipase A2 (PLA2s), hemorrhagic metalloproteinases)
  • 4.4. Global Anti-Venom Market by End User
    • 4.4.1. Hospitals
    • 4.4.2. Clinics
    • 4.4.3. Ambulatory Surgical Centers

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Bioclon Institute
  • 6.2. BTG International Inc.
  • 6.3. CSL Ltd.
  • 6.4. Flynn Pharma
  • 6.5. Haffkine Bio-Pharmaceutical Corp Ltd.
  • 6.6. Incepta Pharmaceuticals Ltd.
  • 6.7. Inosan Biopharma
  • 6.8. Instituto Vital Brazil
  • 6.9. MicroPharm Ltd.
  • 6.10. Merck & Co. Inc.
  • 6.11. Merck KGaA
  • 6.12. Pfizer Inc.
  • 6.13. Rare Disease Therapeutics Inc.
  • 6.14. Sigma-Aldrich Co.
  • 6.15. VINS Bio Products Ltd.

LIST OF TABLES

  • 1. GLOBAL ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY SPECIES, 2022-2030 ($ MILLION)2022-2030 ($ MILLION)
  • 2. GLOBAL SNAKE ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY REGION,2022-2030 ($ MILLION)
  • 3. GLOBAL SCORPION ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL SPIDER ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL OTHERS ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY ANTI-VENOM TYPE, 2022-2030 ($ MILLION)
  • 7. GLOBAL POLYVALENT ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL MONOVALENT ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY MODE OF ACTION, 2022-2030 ($ MILLION)
  • 10. GLOBAL CYTOTOXIC ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY MODE OF ACTION, 2022-2030 ($ MILLION)
  • 11. GLOBAL NEUROTOXIC ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY MODE OF ACTION, 2022-2030 ($ MILLION)
  • 12. GLOBAL HAEMOTOXIC ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY MODE OF ACTION, 2022-2030 ($ MILLION)
  • 13. GLOBAL CARDIOTOXIC ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY MODE OF ACTION, 2022-2030 ($ MILLION)
  • 14. GLOBAL OTHERS ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY MODE OF ACTION, 2022-2030 ($ MILLION)
  • 15. GLOBAL ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 16. GLOBAL ANTI-VENOM IN HOSPITALS MARKET RESEARCH AND ANALYSIS 2022-2030 ($ MILLION)
  • 17. GLOBAL ANTI-VENOM IN CLINICS MARKET RESEARCH AND ANALYSIS 2022-2030 ($ MILLION)
  • 18. GLOBAL ANTI-VENOM IN AMBULATORY SURGICAL CENTERS MARKET RESEARCH AND ANALYSIS 2022-2030 ($ MILLION)
  • 19. GLOBAL ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 20. NORTH AMERICAN ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 21. NORTH AMERICAN ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY SPECIES, 2022-2030 ($ MILLION)
  • 22. NORTH AMERICAN ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY VENOM TYPE, 2022-2030 ($ MILLION)
  • 23. NORTH AMERICAN ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY MODE OF ACTION, 2022-2030 ($ MILLION)
  • 24. NORTH AMERICAN ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 25. EUROPE ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY SPECIES, 2022-2030 ($ MILLION)
  • 26. EUROPE ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY VENOM TYPE, 2022-2030 ($ MILLION)
  • 27. EUROPE ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY MODE OF ACTION, 2022-2030 ($ MILLION)
  • 28. EUROPE ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 29. ASIA-PACIFIC ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY SPECIES, 2022-2030 ($ MILLION)
  • 30. ASIA-PACIFIC ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY VENOM TYPE, 2022-2030 ($ MILLION)
  • 31. ASIA-PACIFIC ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY MODE OF ACTION, 2022-2030 ($ MILLION)
  • 32. ASIA-PACIFIC ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 33. REST OF THE WORLD ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY SPECIES, 2022-2030 ($ MILLION)
  • 34. REST OF THE WORLD ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY VENOM TYPE, 2022-2030 ($ MILLION)
  • 35. REST OF THE WORLD ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY MODE OF ACTION, 2022-2030 ($ MILLION)
  • 36. REST OF THE WORLD ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL ANTI-VENOM MARKET SHARE BY SPECIES, 2022 VS 2030 (%)
  • 2. GLOBAL SNAKE ANTI-VENOM MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL SCORPION ANTI-VENOM MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL SPIDER ANTI-VENOM MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL OTHERS ANTI-VENOM MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY ANTI-VENOM TYPE, 2022 VS 2030 (%)
  • 7. GLOBAL POLYVALENT ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL MONOVALENT ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY MODE OF ACTION, 2022 VS 2030 (%)
  • 10. GLOBAL CYTOTOXIC ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY MODE OF ACTION, 2022 VS 2030 (%)
  • 11. GLOBAL NEUROTOXIC ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY MODE OF ACTION, 2022 VS 2030 (%)
  • 12. GLOBAL HAEMOTOXIC ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY MODE OF ACTION, 2022 VS 2030 (%)
  • 13. GLOBAL CARDIOTOXIC ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY MODE OF ACTION, 2022 VS 2030 (%)
  • 14. GLOBAL OTHERS ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY MODE OF ACTION, 2022 VS 2030 (%)
  • 15. GLOBAL ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY END USER, 2022 VS 2030 (%)
  • 16. GLOBAL ANTI-VENOM IN HOSPITALS MARKET RESEARCH AND ANALYSIS, 2022 VS 2030 (%)
  • 17. GLOBAL ANTI-VENOM IN CLINICS MARKET RESEARCH AND ANALYSIS, 2022 VS 2030 (%)
  • 18. GLOBAL ANTI-VENOM IN AMBULATORY SURGICAL CENTERS MARKET RESEARCH AND ANALYSIS, 2022 VS 2030 (%)
  • 19. GLOBAL ANTI-VENOM MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 20. US ANTI-VENOM MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. CANADA ANTI-VENOM MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. UK ANTI-VENOM MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. FRANCE ANTI-VENOM MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. GERMANY ANTI-VENOM MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. ITALY ANTI-VENOM MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. SPAIN ANTI-VENOM MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. REST OF EUROPE ANTI-VENOM MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. INDIA ANTI-VENOM MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. CHINA ANTI-VENOM MARKET SIZE, 2022-2030 ($ MILLION)
  • 30. JAPAN ANTI-VENOM MARKET SIZE, 2022-2030 ($ MILLION)
  • 31. SOUTH KOREA ANTI-VENOM MARKET SIZE, 2022-2030 ($ MILLION)
  • 32. REST OF ASIA-PACIFIC ANTI-VENOM MARKET SIZE, 2022-2030 ($ MILLION)
  • 33. REST OF THE WORLD ANTI-VENOM MARKET SIZE, 2022-2030 ($ MILLION)